After a chaotic and fierce bidding clash that only burst out into the public view a little more than a week ago, Pfizer has ...

The patient who was hospitalized after receiving Intellia Therapeutics’ CRISPR therapy nex-z has died. | The patient who was ...

Sana Biotechnology, CAMP4 Therapeutics and Crinetics Pharmaceuticals have all used the third quarter to refocus their ...

Eli Lilly’s star oral GLP-1 candidate orforglipron and Novo Nordisk’s Wegovy (semaglutide) were named voucher winners in a ...

Women’s health company Organon is selling off its postpartum uterine bleeding or hemorrhage system to Laborie Medical ...

First, the phase 3 trial of Moderna’s norovirus vaccine had to endure a clinical hold. | First, the phase 3 trial of ...

Eli Lilly has linked its amylin agonist eloralintide to up to 20.1% weight loss at Week 48, encouraging the drugmaker to ...

In the study, published in Science Translational Medicine on Nov. 5, researchers identified proteins expressed on the surface ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

UroGen is handing an anti-CTLA-4 antibody back to Agenus after concluding phase 1 data for the bladder cancer drug didn’t ...

As Novo Nordisk and Pfizer vie for control of Metsera, a new round of takeout proposals has resulted in the obesity biotech ...

Evommune is heading to the New York Stock Exchange this morning via a $150 million IPO the inflammation biotech will use to ...